On August 23, 2019 Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), reported that it has changed its name to AIM ImmunoTech Inc. effective September 3, 2019 (Press release, Hemispherx Biopharma, AUG 23, 2019, View Source [SID1234538968]). Additionally, the Company announced that effective September 3, 2019, the Company’s ticker will change to "AIM." The Company’s common stock will continue to trade on the NYSE American.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Amplified Immunological Modulation — or ‘AIM’ — is what our company is all about. We are delighted to announce this name change, which we believe better reflects the core mission of the Company — developing synergistic immunological agents in the fields of lethal cancers and severe ME/CFS. We are a small company, fighting hard to bring meaningful cures to sick people currently without hope. Our AIM is to help others by advancing immunology and unlocking the human body’s ability to heal itself, in both ME/CFS and in highly lethal malignancies," said CEO Thomas K. Equels. "Further, I am very proud of our extensive clinical pipeline and cost-effective approach. We believe the fact that all our oncology trials are paid for by third-party entities through grants from government, NGOs and leading pharmaceutical companies provides significant validation of our clinical potential and a de facto de-risking of the programs."
Ampligen in Oncology
Five Ampligen clinical trials that are open for enrollment evaluating the safety and ability of Ampligen to increase the effectiveness of cancer immunotherapy, creating synergy for checkpoint blockade drugs by reprogramming the tumor microenvironment
Six additional cancer trials in various pre-enrollment stages using Ampligen plus checkpoint blockade or chemokine modulation
Ampligen in ME/CFS
In the late-stage development/pre-commercial phase for ME/CFS to meet this serious unmet medical need
An Orphan Drug Designation granted by the U.S. Food and Drug Administration in ME/CFS and the U.S. Food and Drug Administration has granted authorization for ME/CFS compassionate care clinics
Received Argentine commercial approval for the treatment of severe ME/CFS in 2016
"We remain highly encouraged by the clinical data to date, which supports the biological activity and strong safety profile of Ampligen," Equels continued. "As such, we look forward to announcing a number of key upcoming catalysts, which we believe will help drive significant shareholder value. As our new name suggests, we are taking AIM at these serious and lethal unmet medical needs."
Go here for a full report on Hemispherx’s ongoing Ampligen clinical trials, its Early Access Program for pancreatic cancer in Europe and its Expanded Access Program for ME/CFS in the United States.